Tohru Ohmori Division of Allergology and Respiratory Medicine, Department of Medicine Showa University School of Medicine Biography Publications Institution JoVE Articles Tohru Ohmori has not added a biography. If you are Tohru Ohmori and would like to personalize this page please email our Author Liaison for assistance. Publications and Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in Molecular Cancer Therapeutics. 01, 2019 | Pubmed ID: 30322949 Receptor Tyrosine Kinase-Targeted Cancer Therapy International Journal of Molecular Sciences. Nov, 2018 | Pubmed ID: 30404198 Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms International Journal of Molecular Sciences. Nov, 2017 | Pubmed ID: 29140271 Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation Molecular Cancer Research : MCR. Jul, 2017 | Pubmed ID: 28289161 Change in Number and Size of Circulating Tumor Cells with High Telomerase Activity During Treatment of Patients with Gastric Cancer Oncology Letters. Dec, 2016 | Pubmed ID: 28105179 Long-term Prognostic Impact of Circulating Tumour Cells in Gastric Cancer Patients World Journal of Gastroenterology. Dec, 2016 | Pubmed ID: 28028372 Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation Molecular Cancer Therapeutics. Dec, 2016 | Pubmed ID: 27612490 Association of Pharmacokinetics and Pharmacogenomics with Safety and Efficacy of Gefitinib in Patients with EGFR Mutation Positive Advanced Non-small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Mar, 2016 | Pubmed ID: 26898617 Prognostic Impact of the Number of Viable Circulating Cells with High Telomerase Activity in Gastric Cancer Patients: a Prospective Study International Journal of Oncology. Jul, 2014 | Pubmed ID: 24788213 Phase II Study of Concurrent Chemoradiotherapy with Carboplatin and Vinorelbine for Locally Advanced Non-small-cell Lung Cancer Molecular and Clinical Oncology. May, 2014 | Pubmed ID: 24772308 Evaluation of the Safety and Efficacy of Combination Chemotherapy with Vinorelbine and Platinum Agents for Patients with Non-small Cell Lung Cancer with Interstitial Lung Disease Anticancer Research. Dec, 2012 | Pubmed ID: 23225454 Relationship of Circulating Tumor Cells to the Effectiveness of Cytotoxic Chemotherapy in Patients with Metastatic Non-small-cell Lung Cancer Oncology Research. 2012 | Pubmed ID: 23193919 MET Increases the Sensitivity of Gefitinib-resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-regulating the Topoisomerase I Activity Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. Sep, 2012 | Pubmed ID: 22722827 [The Mechanisms of Resistance to EGFR-TKIs and Challenges to Overcome Resistance in EGFR Mutant Non-small Cell Lung Cancer] Gan to Kagaku Ryoho. Cancer & Chemotherapy. Jun, 2012 | Pubmed ID: 22705678 Phase II Trial of the Combination of Carboplatin and Irinotecan in Elderly Patients with Small-cell Lung Cancer European Journal of Cancer (Oxford, England : 1990). Jun, 2011 | Pubmed ID: 21458256 Phase II Trial of Amrubicin and Carboplatin in Patients with Sensitive or Refractory Relapsed Small-cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Sep, 2011 | Pubmed ID: 21277039 Phase II Study of S-1, a Novel Oral Fluoropyrimidine, and Biweekly Administration of Docetaxel for Previously Treated Advanced Non-small-cell Lung Cancer Cancer Chemotherapy and Pharmacology. Apr, 2011 | Pubmed ID: 20556612 Are Levels of Pro-gastrin-releasing Peptide or Neuron-specific Enolase at Relapse Prognostic Factors After Relapse in Patients with Small-cell Lung Cancer? Lung Cancer (Amsterdam, Netherlands). Feb, 2011 | Pubmed ID: 20537424 The UGT1A1*28 Genotype and the Toxicity of Low-dose Irinotecan in Patients with Advanced Lung Cancer Oncology Research. 2010 | Pubmed ID: 20377135 [Chemotherapy-induced Myelosuppression and Treatment Efficacy in Limited-stage Disease Small Cell Lung Cancer] Gan to Kagaku Ryoho. Cancer & Chemotherapy. Feb, 2010 | Pubmed ID: 20154478 EGFR Gene Alterations As a Prognostic Biomarker in Advanced Esophageal Squamous Cell Carcinoma Frontiers in Bioscience (Landmark Edition). Jan, 2010 | Pubmed ID: 20036807 Induction Chemoradiotherapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer Oncology Reports. Nov, 2009 | Pubmed ID: 19787234 Combination Effect Between Bortezomib and Tumor Necrosis Factor Alpha on Gefitinib-resistant Non-small Cell Lung Cancer Cell Lines Anticancer Research. Jun, 2009 | Pubmed ID: 19528497 Phase II Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer Anticancer Research. May, 2009 | Pubmed ID: 19443395 Patient Willingness to Undergo Chemotherapy and Thoracic Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Psycho-oncology. May, 2009 | Pubmed ID: 18942662 Effectiveness of Intensive Follow-up After Response in Patients with Small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Feb, 2008 | Pubmed ID: 17900754 Phase I Study of the Combination of Nedaplatin and Weekly Paclitaxel in Patients with Advanced Non-small Cell Lung Cancer Cancer Chemotherapy and Pharmacology. Apr, 2008 | Pubmed ID: 17589845 Mutant Epidermal Growth Factor Receptor Undergoes Less Protein Degradation Due to Diminished Binding to C-Cbl Anticancer Research. Jul-Aug, 2007 | Pubmed ID: 17695511 Phase II Study of Biweekly Administration of Docetaxel and Irinotecan in Patients with Refractory or Relapsed Advanced Non-small Cell Lung Cancer Cancer Chemotherapy and Pharmacology. Jul, 2007 | Pubmed ID: 17273827 Phase II Study of the Combination of Gemcitabine and Nedaplatin for Advanced Non-small-cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). May, 2006 | Pubmed ID: 16563558 The Combination of Cisplatin and Vinorelbine with Concurrent Thoracic Radiation Therapy for Locally Advanced Stage IIIA or IIIB Non-small-cell Lung Cancer Cancer Chemotherapy and Pharmacology. Sep, 2006 | Pubmed ID: 16331494 Enhancement of Sensitivity to Tumor Necrosis Factor Alpha in Non-small Cell Lung Cancer Cells with Acquired Resistance to Gefitinib Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Dec, 2005 | Pubmed ID: 16361577 Patients Preferences in Chemotherapy for Advanced Non-small-cell Lung Cancer Internal Medicine (Tokyo, Japan). Feb, 2005 | Pubmed ID: 15750269 Phase II Study of Irinotecan and Carboplatin in Patients with the Refractory or Relapsed Small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Jun, 2003 | Pubmed ID: 12781433 Phase I Study of the Combination of Gemcitabine and Nedaplatin for Treatment of Previously Untreated Advanced Non-small Cell Lung Cancer Lung Cancer (Amsterdam, Netherlands). Jan, 2003 | Pubmed ID: 12499100 Antitumor Activity of the Selective Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing Multidrug-resistant Cell Line in Vitro and in Vivo International Journal of Cancer. Mar, 2002 | Pubmed ID: 11857424 स्थापना और तीन Afatinib प्रतिरोधी फेफड़े Adenocarcinoma पीसी-9 सेल लाइन्स की विशेषता Afatinib की बढ़ती खुराक के साथ विकसित Toshimitsu Yamaoka1, Motoi Ohba1, Yuki Matsunaga2, Junji Tsurutani1, Tohru Ohmori3 1Advanced Cancer Translational Research Institute, Showa University, 2Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine JoVE 59473 암 연구학 एक 2-कदम खुराक-वृद्धि प्रक्रिया के साथ फेफड़ों ग्रंथिकर्कटता कोशिकाओं में इन विट्रो में EGFR-TKI और TKI से मुलाकात के लिए दोहरी प्रतिरोध की स्थापना Toshimitsu Yamaoka1, Motoi Ohba1, Satoru Arata1,2, Tohru Ohmori1 1Institute of Molecular Oncology, Showa University, 2Center for Biotechnology, Showa University JoVE 55967 암 연구학
स्थापना और तीन Afatinib प्रतिरोधी फेफड़े Adenocarcinoma पीसी-9 सेल लाइन्स की विशेषता Afatinib की बढ़ती खुराक के साथ विकसित Toshimitsu Yamaoka1, Motoi Ohba1, Yuki Matsunaga2, Junji Tsurutani1, Tohru Ohmori3 1Advanced Cancer Translational Research Institute, Showa University, 2Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 3Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine JoVE 59473 암 연구학
एक 2-कदम खुराक-वृद्धि प्रक्रिया के साथ फेफड़ों ग्रंथिकर्कटता कोशिकाओं में इन विट्रो में EGFR-TKI और TKI से मुलाकात के लिए दोहरी प्रतिरोध की स्थापना Toshimitsu Yamaoka1, Motoi Ohba1, Satoru Arata1,2, Tohru Ohmori1 1Institute of Molecular Oncology, Showa University, 2Center for Biotechnology, Showa University JoVE 55967 암 연구학
